AIM
DGX icon

Acrospire Investment Management’s Quest Diagnostics DGX Stock Holding History

Acrospire Investment Management’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-1,600
Closed -$178K – 398
2017
Q2 		$178K Buy
1,600
+1,200
+300% +$127K 0.17% 35
2017
Q1 		$39K Sell
400
-1,400
-78% -$133K 0.03% 1147
2016
Q4 		$165K Buy
1,800
+1,300
+260% +$112K 0.07% 515
2016
Q3 		$42K Hold
500
– – 0.03% 1166
2016
Q2 		$41K Sell
500
-100
-17% -$7.62K 0.03% 1202
2016
Q1 		$43K Buy
+600
New +$40.2K 0.03% 1078

Other funds holding DGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
APG Asset Management
APG Asset Management Amsterdam, Netherlands $31.6B AUM 19.33% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
AL
AJO LP Philadelphia, Pennsylvania $199M AUM 109.68% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Acrospire Investment Management's DGX Position: Q3 2017 in Review

Acrospire Investment Management sold out of Quest Diagnostics (DGX) in Q3 2017, closing a stake of 1,600 shares — an estimated $178K sold.

Acrospire Investment Management first reported a position in DGX in Q1 2016 and held it in 6 quarters. The position peaked at $178K in Q2 2017. 616 funds tracked by Wall St. Rank hold DGX as of Q3 2017.

  • Acrospire Investment Management reported no remaining Quest Diagnostics position as of Q3 2017 after selling out during the quarter.
  • Acrospire Investment Management sold 1,600 Quest Diagnostics shares in Q3 2017, an estimated $178K.
  • Acrospire Investment Management first reported a position in Quest Diagnostics in Q1 2016 and held it in 6 quarters.
  • Acrospire Investment Management's Quest Diagnostics position peaked at $178K in Q2 2017.
  • 616 funds tracked by Wall St. Rank held Quest Diagnostics as of Q3 2017.

Based on Acrospire Investment Management's 13F filing for Q3 2017, filed 26 Oct 2017.